Changes Michael Shan: Added medians and HRs Jeff Humphrey/Susan Kelley/Rita: Added 44% increase in OS Lisa Melilli: Changed FHSI-TSP statement to her exact wording Points to Consider Should we add % improvement in TTP? Marius: add “clinically meaningful” to 1 st bullet Howard Snow: add bullet that safety was consistent with TARGETs
Changes Susan Kelley/Robert Rosen: Added bullet to tie in MOA story Dimitris: Changed final bullet from “first-line” from “first-systemic Dimitris: Added subbullet on sorafenib clinical benefit in HCC Points to Consider 1. Jim Partyka: 3 rd bullet somewhat overstepping. Consider instead “this study demonstrates that sorafenib is safe and effective in the first-line treatment of HCC”